Solid Tumor – Pipeline Review, H1 2012
Solid Tumor – Pipeline Review, H1 2012
Reference Code: GMDHC1622IDB
Publication Date: January 2012
Solid Tumor – Pipeline Review, H1 2012 GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Solid Tumor – Pipeline Review, H1 2012
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables ............................................................................................................................................................................... 11
List of Figures .............................................................................................................................................................................. 21
Introduction....................................................................................................................................................................................... 22
Global Markets Direct Report Coverage ...................................................................................................................................... 22
Solid Tumor Overview ...................................................................................................................................................................... 23
Therapeutics Development............................................................................................................................................................... 24
An Overview of Pipeline Products for Solid Tumor ...................................................................................................................... 24
Solid Tumor Therapeutics under Development by Companies ........................................................................................................ 26
Solid Tumor Therapeutics under Investigation by Universities/Institutes.......................................................................................... 47
Late Stage Products ......................................................................................................................................................................... 60
Comparative Analysis .................................................................................................................................................................. 60
Mid Clinical Stage Products.............................................................................................................................................................. 61
Comparative Analysis .................................................................................................................................................................. 61
Early Clinical Stage Products ........................................................................................................................................................... 62
Comparative Analysis .................................................................................................................................................................. 62
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 63
Comparative Analysis .................................................................................................................................................................. 63
Solid Tumor Therapeutics – Products under Development by Companies ...................................................................................... 64
Solid Tumor Therapeutics – Products under Investigation by Universities/Institutes...................................................................... 117
Companies Involved in Solid Tumor Therapeutics Development ................................................................................................... 166
Bristol-Myers Squibb Company ................................................................................................................................................. 166
Genzyme Corporation ............................................................................................................................................................... 167
Johnson & Johnson ................................................................................................................................................................... 168
Boehringer Ingelheim GmbH ..................................................................................................................................................... 169
F. Hoffmann-La Roche Ltd. ....................................................................................................................................................... 170
Kyowa Hakko Kirin Co., Ltd. ...................................................................................................................................................... 171
Abbott Laboratories ................................................................................................................................................................... 172
Biogen Idec Inc. ......................................................................................................................................................................... 173
Shionogi & Co., Ltd.................................................................................................................................................................... 174
Amgen Inc. ................................................................................................................................................................................ 175
Sanofi-Aventis ........................................................................................................................................................................... 176
Adherex Technologies Inc. ........................................................................................................................................................ 177
AstraZeneca PLC ...................................................................................................................................................................... 178
Eli Lilly and Company ................................................................................................................................................................ 179
GlaxoSmithKline plc .................................................................................................................................................................. 180
Seattle Genetics, Inc. ................................................................................................................................................................ 181
Tekmira Pharmaceuticals Corp. ................................................................................................................................................ 182
Genentech, Inc. ......................................................................................................................................................................... 183
Nektar Therapeutics .................................................................................................................................................................. 185
MedImmune LLC ....................................................................................................................................................................... 186
Gilead Sciences, Inc. ................................................................................................................................................................. 187
Solid Tumor – Pipeline Review, H1 2012 GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Solid Tumor – Pipeline Review, H1 2012
Biotest AG ................................................................................................................................................................................. 188
Daiichi Sankyo Company, Ltd.................................................................................................................................................... 189
Merck & Co., Inc. ....................................................................................................................................................................... 190
Dainippon Sumitomo Pharma Co., Ltd. ..................................................................................................................................... 192
Cangene Corporation ................................................................................................................................................................ 193
Oxford BioMedica plc ................................................................................................................................................................ 194
Micromet, Inc. ............................................................................................................................................................................ 195
Scil Proteins GmbH ................................................................................................................................................................... 196
Infinity Pharmaceuticals, Inc. ..................................................................................................................................................... 197
Takeda Pharmaceutical Company Limited ................................................................................................................................ 198
YM BioSciences Inc................................................................................................................................................................... 199
Light Sciences Oncology, Inc. ................................................................................................................................................... 200
Ipsen S.A. .................................................................................................................................................................................. 201
Nanotherapeutics, Inc................................................................................................................................................................ 202
Prolexys Pharmaceuticals, Inc................................................................................................................................................... 203
Bio-Path Holdings, Inc. .............................................................................................................................................................. 204
Ambrilia Biopharma Inc. ............................................................................................................................................................ 205
Aposense Ltd............................................................................................................................................................................. 206
ZIOPHARM Oncology, Inc. ........................................................................................................................................................ 207
Millennium Pharmaceuticals, Inc. .............................................................................................................................................. 208
Novartis AG ............................................................................................................................................................................... 209
ImClone Systems Incorporated ................................................................................................................................................. 211
Astellas Pharma Inc................................................................................................................................................................... 212
BioMarin Pharmaceutical Inc. .................................................................................................................................................... 213
Cephalon, Inc. ........................................................................................................................................................................... 214
Chong Kun Dang Pharmaceutical ............................................................................................................................................. 215
Chugai Pharmaceutical Co. Ltd ................................................................................................................................................. 216
Daewoong Pharmaceutical Co., Ltd. ......................................................................................................................................... 217
Eisai Co., Ltd. ............................................................................................................................................................................ 218
Genta Incorporated.................................................................................................................................................................... 219
GTC Biotherapeutics, Inc. ......................................................................................................................................................... 220
ImmunoGen, Inc. ....................................................................................................................................................................... 221
Kowa Company, Ltd. ................................................................................................................................................................. 222
Nippon Kayaku Co., Ltd............................................................................................................................................................. 223
Ono Pharmaceutical Co., Ltd..................................................................................................................................................... 224
OSI Pharmaceuticals, Inc. ......................................................................................................................................................... 225
Pfizer Inc.................................................................................................................................................................................... 226
Sunesis Pharmaceuticals, Inc.................................................................................................................................................... 228
SuperGen, Inc. .......................................................................................................................................................................... 229
Taiho Pharmaceutical Co., Ltd. ................................................................................................................................................. 230
Takara Holdings Inc................................................................................................................................................................... 231
Teva Pharmaceutical Industries Limited .................................................................................................................................... 232
Cell Therapeutics, Inc. ............................................................................................................................................................... 233
Genmab A/S .............................................................................................................................................................................. 234
Solid Tumor – Pipeline Review, H1 2012 GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3)
Solid Tumor – Pipeline Review, H1 2012
Progenics Pharmaceuticals, Inc. ............................................................................................................................................... 235
Enzon Pharmaceuticals, Inc. ..................................................................................................................................................... 236
Santaris Pharma A/S ................................................................................................................................................................. 237
Silence Therapeutics plc. .......................................................................................................................................................... 238
Calando Pharmaceuticals, Inc. .................................................................................................................................................. 239
Exelixis, Inc................................................................................................................................................................................ 240
Aduro BioTech ........................................................................................................................................................................... 241
Cyclacel Pharmaceuticals Inc. ................................................................................................................................................... 242
Celgene Corporation ................................................................................................................................................................. 243
Onyx Pharmaceuticals, Inc. ....................................................................................................................................................... 244
Bayer AG ................................................................................................................................................................................... 245
Incyte Corporation ..................................................................................................................................................................... 246
Geron Corporation ..................................................................................................................................................................... 247
MannKind Corporation............................................................................................................................................................... 248
Merck KGaA .............................................................................................................................................................................. 249
Access Pharmaceuticals, Inc. .................................................................................................................................................... 250
4SC AG ..................................................................................................................................................................................... 251
EntreMed, Inc. ........................................................................................................................................................................... 252
EpiCept Corporation .................................................................................................................................................................. 253
Genesis Research and Development Corporation Ltd. ............................................................................................................. 254
Hana Biosciences, Inc. .............................................................................................................................................................. 255
Celldex Therapeutics, Inc. ......................................................................................................................................................... 256
AEterna Zentaris Inc. ................................................................................................................................................................. 257
ImmunoCellular Therapeutics, Ltd. ............................................................................................................................................ 258
Ariad Pharmaceuticals, Inc. ....................................................................................................................................................... 259
Lorus Therapeutics Inc .............................................................................................................................................................. 260
Marshall Edwards, Inc. .............................................................................................................................................................. 261
MediciNova, Inc. ........................................................................................................................................................................ 262
Basilea Pharmaceutica Ltd. ....................................................................................................................................................... 263
MethylGene Inc ......................................................................................................................................................................... 264
Bionomics Limited ..................................................................................................................................................................... 265
MultiCell Technologies, Inc. ....................................................................................................................................................... 266
Circadian Technologies Limited................................................................................................................................................. 267
Oncolytics Biotech Inc. .............................................................................................................................................................. 268
Oncothyreon Inc ........................................................................................................................................................................ 269
OncoVista Innovative Therapies, Inc. ........................................................................................................................................ 270
OXiGENE, Inc............................................................................................................................................................................ 271
Patrys Limited ............................................................................................................................................................................ 272
Peregrine Pharmaceuticals, Inc. ................................................................................................................................................ 273
Curis, Inc. .................................................................................................................................................................................. 274
Anadys Pharmaceuticals, Inc .................................................................................................................................................... 275
ARQULE, INC............................................................................................................................................................................ 276
ADVENTRX Pharmaceuticals.................................................................................................................................................... 277
Alexion Pharmaceuticals, Inc..................................................................................................................................................... 278
Solid Tumor – Pipeline Review, H1 2012 GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(4)
Solid Tumor – Pipeline Review, H1 2012
Cytokinetics, Inc ........................................................................................................................................................................ 279
TopoTarget A/S ......................................................................................................................................................................... 280
Mundipharma International Limited ........................................................................................................................................... 281
CytRx Corporation ..................................................................................................................................................................... 282
Regeneron Pharmaceuticals, Inc............................................................................................................................................... 283
Oncogenex Pharmaceuticals, Inc. ............................................................................................................................................. 284
Pharmacyclics, Inc..................................................................................................................................................................... 285
Dendreon Corporation ............................................................................................................................................................... 286
Array BioPharma Inc. ................................................................................................................................................................ 287
Thallion Pharmaceuticals Inc. .................................................................................................................................................... 288
Transgene SA............................................................................................................................................................................ 289
Progen Pharmaceuticals Limited ............................................................................................................................................... 290
TapImmune Inc.......................................................................................................................................................................... 291
Jiangsu Hengrui Medicine Co., Ltd. ........................................................................................................................................... 292
Threshold Pharmaceuticals, Inc. ............................................................................................................................................... 293
Galapagos NV ........................................................................................................................................................................... 294
Synta Pharmaceuticals Corp. .................................................................................................................................................... 295
CrystalGenomics, Inc. ............................................................................................................................................................... 296
Natco Pharma Limited ............................................................................................................................................................... 297
Oasmia Pharmaceutical AB ....................................................................................................................................................... 298
Algeta ASA ................................................................................................................................................................................ 299
Protox Therapeutics Inc............................................................................................................................................................. 300
e-Therapeutics plc ..................................................................................................................................................................... 301
Rexahn Pharmaceuticals, Inc. ................................................................................................................................................... 302
SymBio Pharmaceuticals Limited .............................................................................................................................................. 303
Eisai Inc. .................................................................................................................................................................................... 304
Morphotek, Inc. .......................................................................................................................................................................... 305
Spectrum Pharmaceuticals, Inc. ................................................................................................................................................ 306
Debiopharm Group .................................................................................................................................................................... 307
Chroma Therapeutics Ltd. ......................................................................................................................................................... 308
Colby Pharmaceutical Company ............................................................................................................................................... 309
Affimed Therapeutics AG .......................................................................................................................................................... 310
Wilex AG ................................................................................................................................................................................... 311
INSYS Therapeutics, Inc. .......................................................................................................................................................... 312
Ambit Biosciences Corporation.................................................................................................................................................. 313
Philogen S.p.A. .......................................................................................................................................................................... 314
Acceleron Pharma, Inc. ............................................................................................................................................................. 315
Pieris AG ................................................................................................................................................................................... 316
Glycotope GmbH ....................................................................................................................................................................... 317
Neovacs SA ............................................................................................................................................................................... 318
ERYtech Pharma ....................................................................................................................................................................... 319
Curacyte AG .............................................................................................................................................................................. 320
Apogenix GmbH ........................................................................................................................................................................ 321
BioNumerik Pharmaceuticals, Inc. ............................................................................................................................................. 322
Solid Tumor – Pipeline Review, H1 2012 GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(5)
Solid Tumor – Pipeline Review, H1 2012
Altor BioScience Corporation..................................................................................................................................................... 323
Provecs Medical GmbH ............................................................................................................................................................. 324
EnGeneIC Ltd ............................................................................................................................................................................ 325
Angiogene Pharmaceuticals Ltd. ............................................................................................................................................... 326
GenSpera, Inc. .......................................................................................................................................................................... 327
Phoenix Biotechnology, Inc. ...................................................................................................................................................... 328
Allozyne, Inc. ............................................................................................................................................................................. 329
Coronado Biosciences, Inc. ....................................................................................................................................................... 330
Cerulean Pharma, Inc................................................................................................................................................................ 331
MacroGenics, Inc....................................................................................................................................................................... 332
Pervasis Therapeutics, Inc. ....................................................................................................................................................... 333
Pharmascience Inc. ................................................................................................................................................................... 334
Arno Therapeutics, Inc. ............................................................................................................................................................. 335
ACT Biotech, Inc........................................................................................................................................................................ 336
OncoMed Pharmaceuticals, Inc. ................................................................................................................................................ 337
TetraLogic Pharmaceuticals ...................................................................................................................................................... 338
Boston Biomedical, Inc. ............................................................................................................................................................. 339
Five Prime Therapeutics, Inc. .................................................................................................................................................... 340
PanaGin Pharmaceuticals Inc. .................................................................................................................................................. 341
Vaccinex, Inc. ............................................................................................................................................................................ 342
Azaya Therapeutics, Inc. ........................................................................................................................................................... 343
Semafore Pharmaceuticals, Inc. ................................................................................................................................................ 344
CanBas Co., Ltd. ....................................................................................................................................................................... 345
S*BIO Pte Ltd ............................................................................................................................................................................ 346
Merrimack Pharmaceuticals, Inc................................................................................................................................................ 347
PTC Therapeutics, Inc. .............................................................................................................................................................. 348
RESprotect GmbH ..................................................................................................................................................................... 349
Conatus Pharmaceuticals Inc. ................................................................................................................................................... 350
Deciphera Pharmaceuticals, LLC .............................................................................................................................................. 351
ProNAi Therapeutics, Inc........................................................................................................................................................... 352
Mersana Therapeutics, Inc. ....................................................................................................................................................... 353
Vascular Biogenics Ltd. ............................................................................................................................................................. 354
Jennerex Biotherapeutics, Inc. .................................................................................................................................................. 355
Stemline Therapeutics, Inc. ....................................................................................................................................................... 356
Axelar AB................................................................................................................................................................................... 357
Endocyte, Inc. ............................................................................................................................................................................ 358
Proacta, Inc. .............................................................................................................................................................................. 359
Cornerstone Pharmaceuticals, Inc............................................................................................................................................. 360
Omnitura Therapeutics Inc. ....................................................................................................................................................... 361
Advenchen Laboratories, LLC ................................................................................................................................................... 362
AndroScience Corporation ........................................................................................................................................................ 363
Onconova Therapeutics, Inc ...................................................................................................................................................... 364
MolMed S.p.A. ........................................................................................................................................................................... 365
Intellikine, Inc. ............................................................................................................................................................................ 366
Solid Tumor – Pipeline Review, H1 2012 GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(6)
Solid Tumor – Pipeline Review, H1 2012
Syndax Pharmaceuticals, Inc. ................................................................................................................................................... 367
Myriad Pharmaceuticals, Inc...................................................................................................................................................... 368
NOXXON Pharma AG ............................................................................................................................................................... 369
NovaLead Pharma Pvt. Ltd........................................................................................................................................................ 370
Esperance Pharmaceuticals, Inc. .............................................................................................................................................. 371
Mirna Therapeutics, Inc. ............................................................................................................................................................ 372
Transtech Pharma, Inc. ............................................................................................................................................................. 373
BiPar Sciences, Inc. .................................................................................................................................................................. 374
Xencor, Inc. ............................................................................................................................................................................... 375
ImmunoVaccine Technologies Inc. ............................................................................................................................................ 376
Welichem Biotech Inc. ............................................................................................................................................................... 377
Oncolys BioPharma Inc. ............................................................................................................................................................ 378
APEIRON Biologics AG ............................................................................................................................................................. 379
HENKAN Pharmaceutical Co., Ltd. ........................................................................................................................................... 380
Immunocore Limited. ................................................................................................................................................................. 381
BIND Biosciences, Inc. .............................................................................................................................................................. 382
NewLink Genetics Corporation .................................................................................................................................................. 383
Tragara Pharmaceuticals, Inc. ................................................................................................................................................... 384
Taiwan Liposome Company ...................................................................................................................................................... 385
Drais Pharmaceuticals, Inc. ....................................................................................................................................................... 386
PharmaMar, S.A. ....................................................................................................................................................................... 387
Kiadis Pharma B.V. ................................................................................................................................................................... 388
Quintessence Biosciences, Inc. ................................................................................................................................................. 389
Bellicum Pharmaceuticals, Inc. .................................................................................................................................................. 390
VentiRx Pharmaceuticals, Inc. ................................................................................................................................................... 391
KaloBios Pharmaceuticals, Inc. ................................................................................................................................................. 392
AB Science ................................................................................................................................................................................ 393
arGEN-X BV .............................................................................................................................................................................. 394
Kinex Pharmaceuticals, LLC...................................................................................................................................................... 395
Adamis Pharmaceuticals Corporation ....................................................................................................................................... 396
SynDevRx™, Inc. ...................................................................................................................................................................... 397
Tigris Pharmaceuticals, Inc........................................................................................................................................................ 398
to-BBB technologies BV ............................................................................................................................................................ 399
Cylene Pharmaceuticals, Inc. .................................................................................................................................................... 400
Nereus Pharmaceuticals, Inc. ....